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ABSTRACT
Background The genetic basis for developing asthma
has been extensively studied. However, association
studies to date have mostly focused on mild to moderate
disease and genetic risk factors for severe asthma
remain unclear.
Objective To identify common genetic variants affecting
susceptibility to severe asthma.
Methods A genome-wide association study was
undertaken in 933 European ancestry individuals with
severe asthma based on Global Initiative for Asthma
(GINA) criteria 3 or above and 3346 clean controls. After
standard quality control measures, the association of
480 889 genotyped single nucleotide polymorphisms
(SNPs) was tested. To improve the resolution of the
association signals identified, non-genotyped SNPs were
imputed in these regions using a dense reference panel
of SNP genotypes from the 1000 Genomes Project. Then
replication of SNPs of interest was undertaken in
a further 231 cases and 1345 controls and
a meta-analysis was performed to combine the results
across studies.
Results An association was confirmed in subjects with
severe asthma of loci previously identified for association
with mild to moderate asthma. The strongest evidence
was seen for the ORMDL3/GSDMB locus on
chromosome 17q12-21 (rs4794820, p¼1.03310(8)
following meta-analysis) meeting genome-wide
significance. Strong evidence was also found for the
IL1RL1/IL18R1 locus on 2q12 (rs9807989,
p¼5.59310(8) following meta-analysis) just
below this threshold. No novel loci for susceptibility to
severe asthma met strict criteria for genome-wide
significance.
Conclusions The largest genome-wide association
study of severe asthma to date was carried out and
strong evidence found for the association of two
previously identified asthma susceptibility loci in patients
with severe disease. A number of novel regions with
suggestive evidence were also identified warranting
further study.
INTRODUCTION
Asthma is a chronic inﬂammatory condition of the
airways characterised by recurrent episodes of
reversible airway obstruction and increased bron-
chial hyper-responsiveness.1 Approximately 10% of
patients with asthma are prone to severe exacer-
bations and remain symptomatic despite treatment
with high-dose inhaled corticosteroids (ICS) and
long-acting b2-adrenergic receptor agonists.2 This
subgroup of patients disproportionately consume
healthcare resources related to asthma and
contribute the largest proportion of morbidity and
mortality.3
The genetic basis for developing asthma has been
extensively investigated; numerous candidate genes
have been studied for association with asthma due
to the potential biological effects on airway func-
tion of the relevant gene products, although repli-
cation has been inconsistent.4e10 In addition,
recent genome-wide association studies (GWAS) in
asthma have identiﬁed a widely replicated locus on
chromosome 17q12-21 containing genes ORMDL3,
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CCL11 and GSDML, and additional genes including CHI3L1,
IL1RL1 and WDR36 on chromosomes 1q31, 2q12, and 5q22
respectively.11e13
Recently, the biggest collaborative effort thus far investigating
the genetic determinants of asthma was published by the
GABRIEL consortium. This study consisted of 10 365 case
subjects and 16 110 controls and observed genome-wide signiﬁ-
cance between asthma and single nucleotide polymorphisms
(SNPs) within previously reported loci and genes, including
genes IL18R1, HLA-DQ, IL33, and chromosome 17q12-21, the
latter speciﬁc to childhood-onset disease.14 Subsequently, a large
Australian collaborative effort carried out a GWAS in 2669 cases
and 4528 controls. A selected number of identiﬁed loci were then
followed up in a replication analysis following a meta-analysis
with the results of the GABRIEL study. This paper provided
independent support for loci reported by GABRIEL: IL18R1, IL33,
ORMDL3 and IL2RB, and identiﬁed a further two loci reaching
genome-wide signiﬁcance in the combined analysis of all studies
(n¼57 800): IL6R and chromosome 11q13.5.15
Furthermore, the EVE consortium conducted a meta-analysis
of North-American GWAS (n¼5416 in meta-analysis, n¼12 649
in replication) inclusive of individuals of European American,
African American or African Caribbean, and Latino ancestry.
This study reported that previously identiﬁed loci on 17q21, near
IL1RL1, TSLP and IL33, were robust to ethnic differences
showing signiﬁcant association in all three ethnic groups.16
In addition, a single small GWAS (473 cases, 1892 controls)
was conducted in 2009 on a population of patients with severe
or difﬁcult to treat asthma from The Epidemiology and Natural
History of Asthma: Outcomes and Treatment Regimes
(TENOR) study and identiﬁed association with multiple SNPs
in the RAD50-IL13 and HLA-DR/DQ regions, although no loci
reached conventional GWAS signiﬁcance criteria.17
These studies have generally involved subjects with mild
asthma. The aims of the current study were ﬁrst to identify
genetic determinants of severe asthma, and second to evaluate
whether susceptibility to severe asthma differs from that of mild
to moderate asthma.
METHODS
Participants
Discovery cohort
We genotyped 1026 individuals of European ancestry with severe
asthma based on the Global Initiative for Asthma (GINA)
criteria.18 Only subjects in classes 3e5 were included, recruited
across UK-based centres. Subjects were selected from individuals
participating in the Difﬁcult/Severe Asthma (BTS) study
(n¼290), supplemented with subjects from other centres. A total
of 3353 control subjects without history of asthma or wheeze
(clean controls) were collected from the UK and Western
Australia, all of whom were of European ancestry.
Replication cohort
A replication cohort of 231 cases with more severe asthma based
on clinical examination by a respiratory physician and treatment
steps (ie, receiving ICS$400 mg in combination with a long- and
short-acting b2-adrenergic receptor agonists and short-acting
beta-agonist) and 1345 controls without asthma were recruited
by the Australian Asthma Genetics Consortium (AAGC) study.
All individuals from Australia were of European ancestry.
Baseline characteristics and participant recruitment of
all study populations per centre are described in the online
repository.
Genotyping and procedures
Participants were genotyped using the Illumina Human-
Hap550K, 610K, 660K, and 1.2M SNP chip platforms (Illumina,
San Diego, California, USA). To minimise bias due to the use of
different genotyping platforms in case and control cohorts, only
the 490 303 SNPs in common across all six platforms were used.
Furthermore, the use of principal components analysis (PCA)
covariates provides some correction for assay effects.19 We also
excluded any SNPs that showed a signiﬁcant difference in allele
frequencies between the three control groups (p<10(6)).
However, it is not possible to completely eliminate bias due to
genotyping platform and centre and hence we sought replica-
tion. A table describing the number of samples genotyped on
each platform has been included (online table E1). Within each
study, individuals with <90% of SNPs called were excluded and
SNPs were excluded if they had low call rates (proportion of
genotypes called <90%), were not in Hardy-Weinberg equilib-
rium (HWE, p<10(4)), had a low minor allele frequency
(MAF<1%) or with differential missingness between cases and
controls (p<10(4)). PCA was carried out to detect outlying
samples and to correct for residual population structure using
EIGENSOFT V.3.0 (online ﬁgure E1).19
Statistical analyses
Association tests of genotyped SNPs were carried out using PLINK
V.1.07 with an additive genetic model with the ﬁrst 10 principal
components as covariates.20 We tested association with 480889
SNPs present across all cohorts; 21 SNPs showing a signiﬁcant
difference in allele frequencies (p<10(6)) between the three
control groups were removed. We identiﬁed regions of interest as
those with a sentinel SNP showing association with asthma (at
a threshold of p<5310(5)) with at least one additional SNP
within 500 Kb also reaching a threshold of p<5310(5).
1000 Genomes imputation
Imputation was used to improve the resolution of regions
identiﬁed for association from genotyped data. Genotyped SNPs
were used for imputation to 6.9 million SNPs using the June
2010 release of the 1000 Genomes CEU reference panel
comprising 120 individuals genotyped at 6 858 242 SNPs.21
Haplotypes were phased by comparing genotypes across our
4279 cases and controls with all alleles deﬁned on the positive
strand using MaCH.22 Imputation of genotypes was carried out
by comparing haplotype blocks in our phased samples with
those in the 1000 Genomes reference panel using minimac.23 A
measure of conﬁdence in the imputation is given by the metric
r2imp which is an estimate of the correlation between imputed
and true genotypes ranging from 0 to 1 (1 for genotyped SNPs).
Quality control was carried out to exclude SNPs with MAF<1%
or imputation quality r2imp <0.3 (recommended r2imp ﬁlter to
exclude 70% of poorly imputed SNPs).22 Association tests were
performed with ProbABEL using a logistic model with the dose
of the effect allele (on a continuous scale between 0 and 2
reﬂecting imputation uncertainties) as the independent variable
and 10 ancestry principal components derived from our geno-
typed SNPs as covariates.24 Post-association ﬁlters were applied
to remove SNPs showing signiﬁcant association in
controlecontrol comparisons (p<106) leaving 6 103 628 SNPs.
Replication and meta-analysis
Subjects from the AAGC study were used to test replication of
24 SNPs identiﬁed in the discovery GWAS and subsequent
imputation analyses. This SNP list consisted of six genotyped
SNPs from the regions identiﬁed in genotype analyses, four
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imputed SNPs in the same regions with a lower p value than the
original genotyped SNPs, two SNPs with p>10(5) responsible
for secondary peaks in regions with known asthma genes, and
12 SNPs from new regions identiﬁed through imputation. In
order to select the best candidate imputed SNPs for replication
we used a lower p value of <10(5) and a stricter imputation
quality (r2imp$0.7) than used for ﬁne-mapping around geno-
typed SNPs. Statistical signiﬁcance for replication was assessed
using a 5% signiﬁcance threshold and results of inverse-variance
weighted meta-analysis assessed using conventional criteria for
genome-wide signiﬁcance (p¼5310(8)).25
Evaluation of GABRIEL loci
We also investigated the contribution of polymorphisms iden-
tiﬁed for mild to moderate asthma by the GABRIEL consortium
in our severe asthma population. We examined regions within
500 Kb of SNPs reported to be associated with asthma in the
GABRIEL study, including both regions reported to have reached
genome-wide signiﬁcance (p#7.2310(8)) and those providing
suggestive evidence of association (p#5310(7)) in GABRIEL.
Comparison of severe versus mild to moderate asthma
A total of 1028 individuals of European ancestry with a history
of doctor diagnosed asthma at GINA steps 1 or 2 were collected
from the WTCCC2, T1DGC and Busselton populations. A
GWAS was then carried out comparing the 1026 patients with
severe asthma against the 1028 patients with mild to moderate
asthma. All genotyping and quality control procedures were
conducted as above for the severe asthma versus clean control
analyses. We tested association with 488 889 SNPs present across
all cohorts. Imputation was used to improve resolution of
identiﬁed regions and replication was assessed in the AAGC
study using a comparison of the 231 severe cases versus 1085
patients with mild to moderate asthma identiﬁed as never
having received steroid medication in their lifetime.
RESULTS
Genotype data for 933 cases and 3346 controls were available for
the primary discovery analysis after quality control. Replication of
identiﬁed SNPs was assessed in 231 cases and 1345 controls.
Characteristics of the study cohorts are summarised in the online
appendix. The test statistic inﬂation factor l for the discovery
GWAS was modest (l¼1.04). Results shown by the quanti-
leequantile plot suggest the presence of multiple loci with modest
effects (ﬁgure 1A).
In the initial analysis of genotyped data in the discovery
cohort, no SNPs met genome-wide signiﬁcance for association
with severe asthma using a conservative cut-off deﬁned by the
Bonferroni correction: p¼1.04310(7) (ﬁgure 1B). We therefore
went on to evaluate other potential loci with statistical signiﬁ-
cance below this threshold. A total of eight SNPs were identiﬁed
with p<5310(5), with at least one other SNP within 500 kb
with p<5310(5). Assessment for supporting evidence within
the region for these SNPs suggests that six of these loci may
contain susceptibility genes for severe asthma: rs3771166 within
IL18RL1 on 2q12.1 (p¼1.93310(5)), rs11745587 in the 39
untranslated region (UTR) of C5orf56 on 5q31.1
(p¼2.09310(6)), rs9382936 on 6p23 (p¼5.61310(6)) tagging
CD83, rs12699949 on 7p21.1 (p¼1.19310(5)) tagging PRPS1L1,
rs2496764 within an intergenic region on 13q31.1
(p¼7.86310(6)), and rs1810132 within ERBB2 on 17q12-21
(p¼1.73310(5)) (table 1, ﬁgure 2). We did not follow up those
loci characterised by a single SNP within 500 kb showing an
association (p<5310(5)); these loci are listed in online table E4.
Imputation was used to reﬁne association signals within all
six loci. This analysis identiﬁed a further four SNPs with a lower
p value than the original genotyped SNP in ﬁve regions:
rs9807989 on 2q12.1 (p¼5.20310(6)) tagging IL18RL1,
rs12699948 on 7p21.1 (p¼4.84310(6)) tagging PRPS1L1,
rs9547037 intergenic on 13q31.1 (p¼6.60310(6)), and rs9972882
within STARD3 on 17q12-21 (p¼5.17310(6)). Two imputed
SNPs produced secondary peaks in regions with known asthma-
associated genes: rs13035227 on 2q12.1 (p¼8.91310(5)) tagging
IL1RL1, and rs847 in the 39 UTR of IL13 on 5q31 (p¼4.053
10(5)). An additional 12 SNPs with p<10(5) and r2imp¼0.7
produced signals in new regions identiﬁed through imputation
(1.19310(5)#p#2.82310(7)) (table 1, online ﬁgure E2).
Two loci were replicated in the AAGC study cohort. The ﬁrst
of these was on 17q12-21 by rs4794820 tagging the ORMDL3
locus (p¼0.002). The second was on 2q12.1 by a cluster of three
SNPs: rs3771166 within IL18R1 (p¼0.001), rs9807989 tagging
IL18R1 (p¼0.003), and rs13035227 tagging IL1R1 (p¼0.002). In
non-replicated regions, a consistent direction of effect for the
minor allele was seen across studies for 18 out of the 22
remaining SNPs. Following meta-analysis, the signal on
ORMDL3 met conventional genome-wide signiﬁcance
(p¼1.03310(8)) and the signal on IL18RL1 approached this
threshold (p¼5.59310(8)) (table 1, ﬁgure 2).
Next, we proceeded to test all SNPs reported in the GABRIEL
study for both genome-wide signiﬁcance and suggestive evidence
for association with mild to moderate asthma to assess the degree
of association with severe asthma in Asthma UK Genetics of
Severe Asthma (AUGOSA) (online table E2 and E3 and ﬁgure E2).
In general, as might be expected, we also found an association
with these loci apart from rs2284033 on chromosome 22q12
(p¼0.105) and rs11071559 on chromosome 15q22 (p¼0.159).
A comparison of patients with severe asthma versus those
with mild to moderate asthma was carried out (online ﬁgure E3).
The test statistic inﬂation factor l for this GWAS was again
modest (l¼1.04). A single SNP met genome-wide signiﬁcance in
this analysis: rs981516 intergenic on 4p32.1 (p¼3.34310(8), OR
1.50 95% CI 1.30 to 1.73). However, this was not replicated in
the AAGC study (p¼0.451) although the same direction of effect
was seen for the minor allele.
DISCUSSION
We conducted the largest severe asthma GWAS to date in
a cohort of 933 cases deﬁned by GINA steps three or above for
severity and 3346 clean controls to determine if there are
common genetic polymorphisms contributing to susceptibility
to severe asthma.
Overall, we did not identify any novel SNPs meeting genome-
wide signiﬁcance. We carried out further analysis of results for
polymorphisms just below this threshold to look for regions
which did not meet standard genome-wide signiﬁcance but had
supporting evidence with at least one additional SNP with
p<5310(5) within 500 Kb. Using this criterion, we identiﬁed
six loci with suggestive evidence for association. Two of these
loci, chromosomes 2q12 (p¼5.20310(6)) and 17q12-21
(p¼5.17310(5)) implicating the IL1RL1/IL18R1 and ORMDL3/
GSDMB loci respectively have been previously reported by
GWAS for association with mild to moderate asthma.11 13e16
Both of these loci replicated in a second cohort of 231 severe
asthma cases and 1345 controls (2q12, p¼0.001; 17q12-21,
p¼0.002). Evidence for the 17q12-21 locus became genome-wide
signiﬁcant following meta-analysis and was just below this
threshold for the 2q12 locus, highlighting a potentially important
role for these loci in asthma irrespective of severity.
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A previous GWAS in which the main phenotype was blood
eosinophil counts identiﬁed evidence for an association with
asthma for SNPs in IL1RL1 and its ligand, IL33.13 Subsequently,
asthma association of both loci have been shown to be robust to
differences in ancestry.16 We report association with the same
SNP, rs3771166 within IL18R1on chromosome 2q12. Rs3771166
was also reported by the GABRIEL consortium showing the
same direction of effect for association with the minor allele. A
stronger protective effect size is observed for this polymorphism
within our severe asthma cohort (OR¼0.79) compared with
that shown in the GABRIEL study (OR¼0.87).14 With current
data, we are unable to determine if association is driven by the
IL1RL1 or the IL18R1 gene. However, both genes are plausible
biological candidates in the inﬂammatory cascade in the
pathway to asthma pathogenesis.26 27
Associations with asthma and SNPs located on chromosome
17q12-21 have been reported and replicated across multiple
study populations.11 14 28 29 Despite this, the region on 17q12-21
harbours a number of genes of poorly understood function. In
combination with the complex linkage disequilibrium structure
in this locus, it is difﬁcult to be sure which genetic variants are
causal. Furthermore, 17q12-21 has previously been suggested to
be exclusive to childhood-onset disease.11 14 Although, we have
not assessed age of onset in the current study, we found
signiﬁcant association with this locus despite studying
predominantly adult subjects (mean age of disease onset:
21 years), thus challenging this hypothesis.
We report an additional four loci as showing suggestive
evidence of association with severe asthma. The most signiﬁcant
result on chromosome 6p23 implicates CD83, the gene encoding
for the CD83 antigen expressed on dendritic cells and which
may play a role in immune modulation in the airways.30 The
SNP on chromosome 5q31 lies within the 39 UTR of C5orf56,
however it is downstream of the Th2 cytokine genes IL4 and
IL13, and RAD50, a region previously reported for suggestive
association with severe asthma by the TENOR study.17 The
remaining two regions downstream of PRPS1L1 on 7p21 and
intergenic on 13q31 are potentially novel with unknown
function in asthma and warrant further study.
We list in online table E4 those loci not followed up in the
AAGC study due to not meeting our strict predeﬁned threshold
for supporting SNPs in the region (online table E4). Interestingly,
these loci include TSLP, which was identiﬁed as a potential
asthma locus previously.16 We then undertook a MAGENTA31
pathway analysis on the full GWAS dataset to look for enrich-
ment of association in known biological pathways from six
databases (Gene Ontology, Ingenuity Pathway, KEGG, PANTHER
Pathways, PANTHER Molecular Function and PANTHER Bio-
logical Processes). No pathway was signiﬁcant after correction for
multiple testing, although the Fc Epsilon RI Signalling pathway
reached nominal signiﬁcance (p¼0.0014) and includes IL13.
We then went on to assess the contribution of previously
identiﬁed asthma susceptibility loci in patients with severe
disease reported by the recent GABRIEL study.14 As the
GABRIEL study is currently the largest published association
study investigating the genetic determinants of asthma, we
aimed to determine if these signals also contribute to disease
susceptibility in our severe asthma cohort. Individuals in
AUGOSA were included in the total case subjects in the
GABRIEL study. However, as they only constitute a relatively
Figure 1 Quantileequantile plot and
Manhattan plot of study results. (A)
Quantileequantile plot of observed
versus expected log10 p values for all
tested genotyped single nucleotide
polymorphisms (SNPs). (B) Manhattan
plot of e log10 p values for all tested
SNPs against genomic position. *Note:
the signal on chromosome 13q31.1 was
intergenic.
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small proportion (8.9%), an association signal within GABRIEL
for mild to moderate asthma would be unlikely to originate only
from AUGOSA individuals.
For genome-wide signiﬁcant results compared with mild to
moderate asthma from GABRIEL, effect sizes for the risk allele
are greater in our cohort of patients with severe asthma for
rs3771166 on chromosome 2q21: the observed OR for the
protective allele was 0.79 compared with 0.87 in GABRIEL for
rs2305480 on chromosome 17q12-21; the observed OR for the
protective allele was 0.80 compared with 0.85 for rs3894194 on
chromosome 17q12-21; the OR for the risk allele was 1.25
compared with 1.17. Further to this, we show supporting
evidence for loci reported by previous studies such as the
GABRIEL study, including IL13 on 5q31 (p¼9.30310(5)) and
SMAD3 on 15q22.33 (p¼2.88310(4)) containing weaker asso-
ciation signals which fell just below the threshold for signiﬁcance
chosen for our primary analyses.
The explanations behind the increased effect size of risk alleles
in severe asthma are potentially twofold. The most likely
explanation is that the contribution of genetic effects driven by
variation in these genes is greater in patients with more severe
asthma. However, it is possible that in populations with milder
asthma misclassiﬁcation of cases and controls may result in an
underestimate of true effect sizes. Furthermore, differences in
population sizes used in analyses may also reﬂect our varying
ability to determine robust effect sizes.
A comparison of severe versus mild to moderate asthma was
carried out. This identiﬁed a potentially novel locus on 4p32.1
meeting genome-wide signiﬁcance which may be speciﬁc to the
development of severe as opposed to milder forms of asthma.
The sentinel SNP rs981516 is in an intergenic region but in
linkage disequilibrium with rs17291045 (r2¼0.423), a SNP
previously reported to be strongly associated with progression in
HIV-1 infection and may have functional effects on viral
control.32 The identiﬁed SNP was not replicated in the AAGC
study, however given the modest effect size seen in the discovery
GWAS (OR¼1.50), a much larger follow-up cohort would have
been necessary to reliably assess replication.
Although the current study is the largest effort so far to
determine genetic determinants of severe asthma, we are still
limited by the numbers of subjects in being able to generate
enough statistical power to detect all variants with modest
effects. While we can probably exclude major effects being driven
by a single gene as a speciﬁc risk for severe asthma, our data
suggest there may be a number of loci which may be speciﬁc for
severe asthma but with relatively small overall contributions to
the risk of developing severe disease. The obvious solution to
resolving this issue is to undertake further replication studies in
much larger severe asthma populations. However, these popu-
lations by their very deﬁnition are hard to recruit: the current
study included subjects recruited from eight major centres
in the UK and replication in a second study consisting of
subjects recruited from two major centres in Australia. Hence,
obtaining suitable replication populations to take this work
forward will require additional international efforts to establish
appropriately large populations with severe disease.
In summary, we provide evidence to support an enhanced role
for known genetic risk factors for asthma in the development of
severe disease, and also have identiﬁed novel loci which may be
speciﬁc to the development of severe as opposed to milder forms
Table 1 Single nucleotide polymorphisms (SNPs) showing highest association signals for severe asthma
Chromosome Locus SNP Position
AUGOSA (933 cases, 3346 controls) AAGC (231 cases, 1345 controls) Meta-analysis
r2imp OR (95% CI) p Value r
2
imp OR (95% CI) p Value OR (95% CI) p Value
Six genotyped SNPs from regions identified in genotyped SNP analyses
2 IL18R1 rs3771166 102352654 GENO 0.79 (0.71 to 0.88) 1.93310(L5) GENO 0.71 (0.57 to 0.87) 0.001 0.77 (0.70 to 0.85) 1.24310(L7)
5 C5orf56 rs11745587 131824821 GENO 1.30 (1.17 to 1.45) 2.09310(L6) GENO 1.13 (0.92 to 1.39) 0.25 1.26 (1.15 to 1.39) 2.13310(6)
6 CD83 rs9382936 14173097 GENO 1.31 (1.17 to 1.48) 5.61310(L6) GENO 1.00 (0.79 to 1.25) 0.98 1.24 (1.12 to 1.38) 5.68310(5)
7 PRPS1L1 rs12699949 18010787 GENO 0.77 (0.69 to 0.87) 1.19310(L5) GENO 0.89 (0.72 to 1.10) 0.27 0.80 (0.72 to 0.88) 1.19310(5)
13 Intergenic rs2496764 84477159 GENO 1.34 (1.18 to 1.52) 7.86310(L6) GENO 0.99 (0.78 to 1.27) 0.96 1.26 (1.12 to 1.41) 8.03310(5)
17 ERBB2 rs1810132 35119531 GENO 1.28 (1.14 to 1.43) 1.73310(L5) GENO 1.07 (0.86 to 1.32) 0.56 1.23 (1.11 to 1.36) 4.54310(5)
Four imputed SNPs in regions above with a lower p value than the original genotyped SNP in imputed SNP analyses
2 IL18R1 rs9807989 102337632 0.91 0.76 (0.67 to 0.85) 5.20310(L6) 0.91 0.72 (0.58 to 0.89) 0.003 0.75 (0.68 to 0.83) 5.59310(8)
7 PRPS1L1 rs12699948 18010735 0.92 0.75 (0.66 to 0.85) 4.84310(L6) 0.93 0.92 (0.74 to 1.15) 0.46 0.79 (0.71 to 0.88) 1.44310(5)
13 Intergenic rs9547037 84476839 0.90 1.38 (1.20 to 1.58) 6.60310(L6) 0.90 1.00 (0.78 to 1.29) 0.97 1.28 (1.13 to 1.44) 8.01310(5)
17 STARD3 rs9972882 35061224 0.98 1.32 (1.17 to 1.49) 5.17310(L6) 0.99 1.07 (0.85 to 1.34) 0.55 1.26 (1.13 to 1.40) 1.64310(5)
Two SNPs with p>10(5) responsible for secondary peaks in regions with known asthma genes
2 IL1R1 rs13035227 102130269 0.96 1.36 (1.16 to 1.58) 8.91310(L5) GENO 1.53 (1.17 to 1.99) 0.002 1.40 (1.22 to 1.59) 6.69310(7)
5 IL13 rs847 132024568 0.86 1.35 (1.17 to 1.55) 4.05310(L5) 0.94 1.12 (0.88 to 1.43) 0.37 1.29 (1.14 to 1.45) 6.43310(5)
Twelve SNPs from new regions identified by imputation with p<10(5) and r2imp¼0.7 (includes two secondary peaks in previously identified 17q12-21 region)
2 Intergenic chr2:211694960 211694960 0.70 1.76 (1.40 to 2.21) 1.27310(L6) 0.78 1.11 (0.73 to 1.70) 0.62 1.59 (1.30 to 1.94) 6.80310(6)
5 FLJ37543 rs7715669 60972053 GENO 0.74 (0.65 to 0.84) 5.92310(L6) GENO 0.93 (0.74 to 1.18) 0.56 0.78 (0.69 to 0.87) 2.29310(5)
5 NDFIP1 rs6867913 141426164 0.99 0.72 (0.63 to 0.82) 1.74310(L6) 0.97 0.90 (0.69 to 1.15) 0.39 0.75 (0.67 to 0.85) 3.82310(6)
6 GCLC rs9395865 53415653 GENO 0.76 (0.67 to 0.85) 5.27310(L6) GENO 1.15 (0.93 to 1.42) 0.19 0.84 (0.76 to 0.93) 9.27310(4)
6 Intergenic rs6922932 73384242 0.78 0.70 (0.60 to 0.82) 7.36310(L6) 0.83 1.02 (0.79 to 1.31) 0.88 0.78 (0.68 to 0.89) 1.99310(4)
8 DUSP4 rs650230 29322727 0.78 1.37 (1.19 to 1.57) 6.40310(L6) 0.76 1.04 (0.83 to 1.30) 0.73 1.27 (1.13 to 1.42) 5.74310(5)
9 ACO1 rs10970976 32423526 0.98 0.76 (0.67 to 0.86) 9.14310(L6) 0.96 0.84 (0.67 to 1.05) 0.13 0.78 (0.70 to 0.86) 3.69310(6)
11 OR52E4 rs4453217 5883859 0.87 1.43 (1.25 to 1.64) 2.82310(L7) 0.88 0.94 (0.72 to 1.22) 0.63 1.31 (1.16 to 1.48) 1.50310(5)
11 ETS1 rs7125574 127866404 0.93 1.34 (1.18 to 1.51) 5.28310(L6) 0.93 0.92 (0.73 to 1.16) 0.49 1.23 (1.10 to 1.37) 2.13310(4)
17 STAC2 rs9897185 34642935 GENO 1.31 (1.16 to 1.47) 1.19310(L5) GENO 0.95 (0.75 to 1.19) 0.64 1.22 (1.10 to 1.35) 2.50310(4)
17 ORMDL3 rs4794820 35342870 0.94 0.76 (0.68 to 0.85) 1.52310(L6) 0.93 0.72 (0.59 to 0.89) 0.002 0.75 (0.69 to 0.83) 1.03310(8)
19 ZNF665 rs16984547 58373854 GENO 1.53 (1.30 to 1.82) 5.45310(L7) GENO 1.06 (0.76 to 1.49) 0.74 1.43 (1.23 to 1.66) 3.54310(6)
Effect allele refers to the minor allele. GENO denotes genotyped SNP. Significant p values p#0.05 in replication, p<5310(8) in meta-analysis are shown in bold. The gene tagged by the SNP
due to linkage disequilibrium (LD) block structure within the locus is listed.
AAGC, Australian Asthma Genetics Consortium; AUGOSA, Asthma UK Genetics of Severe Asthma.
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Figure 2 Region plots for suggestive loci. The region plots following imputation show the statistical significance of each single nucleotide
polymorphism (SNP) on the elog10 scale as a function of chromosome position (National Center for Biotechnology Information (NCBI) build 36). The
sentinel SNP is shown in blue and the correlation (r2) of each of the surrounding SNPs to the sentinel SNP is shown by their colour (see key). Fine scale
recombination rate is plotted in blue.
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of asthma. These results potentially provide insight into the
biological mechanisms that underlie the regulation of severe
asthma and might help in the discovery of novel therapeutic
targets for disease.
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